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H I G H L I G H T S G R A P H I C A L A B S T R A C T
 The metabolism of deoxynivalenol-
3-glucoside (D3G) was elucidated in
pigs.
 D3G (oral) was nearly completely
hydrolyzed in pigs, but only partially
absorbed.
 Two isomers of deoxynivalenol
(DON) glucuronides were detected
in pig urine.
 Two times less urinary metabolites
were excreted for D3G compared to
DON.
 D3G (i.v.) was almost exclusively
excreted in unmetabolized form via
urine.
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A B S T R A C T
Plants can metabolize the Fusarium mycotoxin deoxynivalenol (DON) by forming the masked mycotoxin
deoxynivalenol-3-b-D-glucoside (D3G). D3G might be cleaved during digestion, thus increasing the total
DON burden of an individual. Due to a lack of in vivo data, D3G has not been included in the various
regulatory limits established for DON so far. The aim of our study was to contribute to the risk assessment
of D3G by determination of its metabolism in pigs. Four piglets received water, D3G (116 mg/kg b.w.) and
the equimolar amount of DON (75 mg/kg b.w.) by gavage on day 1, 5 and 9 of the experiment, respectively.
Additionally, 15.5 mg D3G/kg b.w. were administered intravenously on day 13. Urine and feces were
collected for 24 h and analyzed for DON, D3G, deoxynivalenol-3-glucuronide (DON-3-GlcA),
Abbreviations: 3-ADON, 3-acetyl-deoxynivalenol; 15-ADON, 15-acetyl-deoxynivalenol; b.w., body weight; D3G, deoxynivalenol-3-b-D-glucoside; DON, deoxynivalenol;
DON-3-GlcA, deoxynivalenol-3-glucuronide; DON-15-GlcA, deoxynivalenol-15-glucuronide; DON-GlcA, deoxynivalenol-glucuronide; DOM-1, de-epoxy deoxynivalenol;
DOM-1-GlcA, DOM-1-glucuronide; JECFA, Joint FAO/WHO Expert Committee on Food Additives; MeOH, methanol; LOD, limit of detection; LOQ, limit of quantiﬁcation; MS,
mass spectrometry; MS/MS, tandem mass spectrometry; PBS, phosphate buffered saline; R , apparent recovery; R , recovery of the extraction step; SSE, signal suppression/
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deoxynivalenol-15-GlcA (DON-15-GlcA) and deepoxy-deoxynivalenol (DOM-1) by UHPLC–MS/MS. After
oral application of DON and D3G, in total 84.8  9.7% and 40.3  8.5% of the given dose were detected in
urine, respectively. The majority of orally administered D3G was excreted in form of DON, DON-15-GlcA,
DOM-1 and DON-3-GlcA, while urinary D3G accounted for only 2.6  1.4%. In feces, just trace amounts of
metabolites were found. Intravenously administered D3G was almost exclusively excreted in
unmetabolized form via urine. Data indicate that D3G is nearly completely hydrolyzed in the intestinal
tract of pigs, while the toxin seems to be rather stable after systemic absorption. Compared to DON, the
oral bioavailability of D3G and its metabolites seems to be reduced by a factor of up to 2, approximately.
ã 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Mycotoxins, secondary metabolites of different molds, are
frequent contaminants of food and feed and cause various adverse
health effects in plants, animals and humans. Deoxynivalenol
(DON), mainly produced by Fusarium graminearum and Fusarium
culmorum, is one of the economically most relevant mycotoxins
worldwide (CAST, 2003). DON exhibits its biological activity by
binding to the 60S subunit of eukaryotic ribosomes with
subsequent inhibition of the protein biosynthesis (summarized
by Arunachalam and Doohan, 2013). In animals, DON induces
clinical symptoms like anorexia, emesis, weight loss or immuno-
modulation (reviewed by Pestka, 2007), while the mycotoxin is
associated with outbreaks of gastroenteritis in humans (summa-
rized by Pestka, 2010). As a consequence, regulatory limits in
cereal-based food have been established for DON e.g., by the
European Commission (European Commission, 2006).
In contrast, deoxynivalenol-3-b-D-glucoside (D3G) has not
been included in these regulations so far. This masked mycotoxin is
formed in plants by enzymatic conjugation of glucose to DON
(Poppenberger et al., 2003), thus representing an important
defense mechanism of plants against Fusarium related diseases
(Lemmens et al., 2005). D3G can be found in different cereal crops
(Berthiller et al., 2005; Lancova et al., 2008), as well as in animal
feed and foodstuff (De Boevre et al., 2012; Malachova et al., 2011).
In grains, the molar D3G/DON ratio varies strongly in dependence
on factors like genotype or season, but typically reaches levels of
around 20% (summarized by Berthiller et al., 2013). However, this
ratio can further increase during food processing, resulting in D3G
concentrations even exceeding those of DON (Varga et al., 2013).
Despite its frequent occurrence, toxicological data regarding
D3G are still rare. Poppenberger et al. (2003) showed that D3G
inhibits protein biosynthesis to a far lower extent than its parent
toxin in wheat ribosomes. Nevertheless, there are major concerns
that ingested D3G might be hydrolyzed in the intestinal tract of
mammals, thus releasing its aglycon and increasing the total DON
load of an individual (Joint FAO/WHO Expert Committee on Food
Additives, JECFA, 2011). Although the toxin seems to be rather
stable under conditions simulating early stages of the mammalian
digestion (Berthiller et al., 2011; De Nijs et al., 2012), certain lactic
acid bacteria were capable to cleave D3G in vitro (Berthiller et al.,
2011). Furthermore, incubation of human fecal samples with D3G
resulted in an extensive liberation of DON (Dall´Erta et al., 2013;
Gratz et al., 2013). In 2012, the ﬁrst in vivo reports on the fate of
orally administered D3G in rodents became available (Nagl et al.,
2012; Veršilovskis et al., 2012). Our group demonstrated that D3G
is hydrolyzed in the digestive tract of rats. The liberated DON was
further metabolized, but only poorly absorbed. We therefore
concluded that D3G is of considerably lower toxicological
relevance than DON in rats (Nagl et al., 2012). However, for risk
analysis of D3G more data regarding the toxicity and metabolism of
this masked mycotoxin are urgently needed (JECFA, 2011).
The situation is quite different for DON, whose toxic effects have
been investigated for decades. Notably, major differences in thesusceptibility to DON among animal species were determined,
which are most likely related to species-dependent variations in
the metabolism of DON (summarized by Pestka, 2007). In
principle, ingested DON can be either de-epoxidated by anaerobic
bacteria or conjugated to glucuronic acid by mammalian UDP-
glucuronosyltransferases (UGTs). While the formation of de-epoxy
deoxynivalenol (DOM-1) by ruminal or intestinal microbiota
occurs prior to systemic absorption, glucuronidation of DON has
so far only been described for liver microsomes (reviewed by
Maresca, 2013). Both metabolites, DOM-1 as well as DON-
glucuronide (DON-GlcA) are less cytotoxic than their parent toxin
(Sundstøl Eriksen et al., 2004; Wu et al., 2007). In recent years,
highly sophisticated analytical methods elucidated the metabolic
pattern of DON in more detail. For example, the species-speciﬁc
formation of different DON-GlcA isomers, namely DON-3-glucu-
ronide (DON-3-GlcA), DON-15-glucuronide (DON-15-GlcA), DON-
7-glucuronide and DON-8-glucuronide has been proposed (Maul
et al., 2012; Uhlig et al., 2013; Warth et al., 2013). Furthermore, the
occurrence of novel DON metabolites has been revealed in rats and
chickens (Wan et al., 2014). Generally, pigs are considered to be the
species most sensitive to DON exposure. This might be attributed
to the species’ poor ability to detoxify DON to DOM-1 and the high
absorption rate of unmetabolized DON (Pestka, 2007). As these
characteristics are very similar to what is currently known about
human DON metabolism (reviewed by Turner et al., 2012), swine
can be regarded as most suitable animal model in this research
ﬁeld.
The aim of our study was to elucidate whether D3G has the
potential to be reactivated in vivo by investigation of its
metabolism in pigs. For this purpose, piglets were orally and
intravenously dosed with D3G and their excreta subsequently
analyzed for DON, D3G, DON-3-GlcA, DON-15-GlcA and DOM-1 by
a validated LC–MS/MS based biomarker method. The implemen-
tation of an additional oral DON treatment allowed a comparison
between absorption rates of D3G and its parent toxin. This study
signiﬁcantly extends the current knowledge about D3G metabo-
lism in vivo and therefore facilitates an estimation of the potential
health risk of this masked mycotoxin.
2. Materials and methods
2.1. Chemicals and reagents
Methanol (MeOH, LC grade) and glacial acetic acid (p.a.) were
obtained from VWR International GmbH (Vienna, Austria), while
ammonium acetate (MS grade) and b-glucuronidase (Escherichia
coli, Type IX-A) were purchased from Sigma–Aldrich (Vienna,
Austria). Reagents for preparation of phosphate buffered saline
(PBS; sodium chloride, disodium hydrogen phosphate dihydrate,
sodium dihydrogen phosphate monohydrate) were from Merck
GmbH (Vienna, Austria). Water was puriﬁed using a Purelab Ultra
system (ELGA LabWater, Celle, Germany).
DON and DOM-1 standards were purchased from Romer Labs
GmbH (Tulln, Austria). D3G was either puriﬁed from DON treated
Fig. 1. Experimental design. After an acclimatization period of ﬁve days, four animals received water, D3G and DON by gavage on day 1, 5, and 9, respectively. On day 13, D3G
was administered intravenously. After each of the treatments, animals were separated and urine and feces were collected in two different time periods (0–8 h, 8–24 h after
administration).
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by in vitro enzymatic synthesis and preparative HPLC puriﬁcation
(manuscript in preparation). DON-3-GlcA was produced by
chemical synthesis (Fruhmann et al., 2012). A combined multi
standard stock solution, containing 50 mg/mL DON, D3G, DON-3-
GlcA and DOM-1, was prepared in MeOH and stored at 20 C.
Further dilutions for spiking experiments and calibrants were
prepared in MeOH/water (20/80, v/v).
2.2. Animals and study design
Male crossbred piglets (sow: Landrace  Large White, boar:
Pietrain; 28 days old, 7.1 0.9 kg, non-castrated) were obtained
from a commercial swine producer and allowed to acclimatize for
ﬁve days. Animals were housed pairwise in metabolic cages and
had free access to water. Feed was provided restrictively twice per
day (5% of body weight/day) to ensure fast uptake of the diet.
Before the start of the experiment, the diet was tested for its
concentrations of DON, D3G and acetylated forms of DON (3-
acetyl-deoxynivalenol, 3-ADON; 15-acetyl-deoxynivalenol,
15-ADON).
Using a repeated measures design, the piglets (n = 4) received
water (negative control), D3G (116 mg/kg b.w.) and the equimolar
dose (0.25 mmol/kg b.w.) of DON (75 mg/kg b.w.) per gavage on day
1, 5 and 9 of the experiment, respectively. In addition, D3G was
administered intravenously (15.5 mg/kg b.w., 0.03 mmol/kg b.w.)
on day 13 (Fig. 1). Stock solutions of D3G (1.2 mg/mL) and DON
(1 mg/mL) were prepared by dissolving the solid standards in
water (oral application) or physiological saline (0.9% NaCl,
Fresenius Kabi, Graz, Austria; intravenous application). Volumes
between 700 mL and 1000 mL were administered orally using
polyvinyl chloride catheters (diameter 4.7 mm, length adapted to
size of piglets, Medinorm, Spießen, Germany). Intravenous
administration was performed by cannulation of the ear vein
with sterile catheters (0.9  25 mm, VasoVet distributed by B.
Braun, Melsungen, Germany). After each of the treatments,
animals were separated and urine and feces of individual piglets
were collected for 0–8 h and 8–24 h after dosing. Samples were
frozen and stored at 20 C until further analysis.
The animal experiment was approved by the Institutional Ethics
Committee and the national authority according to x8ff of the
Austrian Law for Animal Experiments, Tierversuchsgesetz – TVG
(GZ 68.205/0236-II/3b/2012).
2.3. Sample preparation
For preparation of urine samples, a dilute-and-shoot approach
was used. After centrifugation (10 min, 14,000  g), 20 mL of urine
samples were added to 180 mL of MeOH/water (20/80, v/v) andvortexed for 15 s. Thereof, 5 mL were injected into the LC–MS/MS
system. In addition, some samples were enzymatically hydrolyzed
to investigate the presence of DOM-1-glucuronide (DOM-1-GlcA).
To this end, 180 mL of PBS (75 mM, pH 7.4) containing 9000 units of
b-glucuronidase were mixed with 20 mL of centrifuged urine
samples. After incubation for 18 h at 37 C, digested samples were
clariﬁed by centrifugation (10 min, 14,000  g) for LC–MS/MS
analysis.
Clean-up of feces samples was performed according to Nagl
et al. (2012). In brief, 250 mg of freeze-dried and homogenized
samples were extracted three times (40/40/20 min) with MeOH/
water (50/50, v/v, 3/2/2 mL). Following protein precipitation with
cold MeOH, aliquots were evaporated and reconstituted in MeOH/
water (20/80, v/v, corresponding to a ﬁnal sample to solvent ratio
of 1:56). Afterwards, samples were centrifuged (10 min,14,000  g)
and 5 mL of the supernatant were injected into the LC–MS/MS
system.
2.4. UHPLC–MS/MS parameters
Analyses were carried out on a 1290 Inﬁnity series UHPLC
system (Agilent Technologies, Waldbronn, Germany) coupled to a
4000 QTrap mass spectrometer (AB Sciex, Foster City, CA) equipped
with a Turbo V electrospray ionization (ESI) source. Chro-
matographic separation was carried out on a Zorbax RRHD Eclipse
XDB-C18 column (2.1 mm  150 mm, 1.8 mm, Agilent Technologies,
Waldbronn, Germany) equipped with a C18 security guard cartridge
(Phenomenex, Aschaffenburg, Germany). Eluent A consisted of
water and eluent B of MeOH/water (97/3, v/v), both containing
0.01% acetic acid and 5 mM ammonium acetate. After an initial
period of 2 min at 5% B, the proportion of B was increased linearly
to 100% (reached at 6.4 min), followed by a hold time of 2 min at
100% B. Afterwards, the column was re-equilibrated for 2 min at 5%
B. The temperature of the column oven was set to 35 C, while 5 mL
of sample volume were injected into a ﬂow of 250 mL/min.
Analytes eluted in the order of DON-3-GlcA (4.9 min), D3G
(5.7 min), DON (5.9 min) and DOM-1 (6.3 min). Mass spectrometric
detection was performed using negative ESI and selective reaction
monitoring mode as described by Nagl et al. (2012).
2.5. Method validation and data evaluation
The determined method performance parameters include
apparent recovery (RA), signal suppression/enhancement (SSE),
recovery of the extraction step (RE), repeatability (RSD), as well as
limits of detection (LODs) and quantiﬁcation (LODs). Prior and after
extraction, blank urine and feces samples (collected from piglets
after negative control treatment) were spiked with standard
compounds in triplicates at 5 and 4 spiking levels, respectively. The
Table 1
Method performance parameters for the pig urine (n = 15) and feces (n = 12).
Matrix Analyte RAa RSD
(%)
SSEb RSD
(%)
RE
c RSD
(%)
LODd (ng/
mL)
LOQd
(ng/
mL)
Urine DON 56  1 56  9 102  9 0.9 8.0
D3G 62  9 62  4 100  5 1.3 2.1
DON-3-
GlcA
114  3 122  8 94  10 9.0 37.3
DOM-1 73  2 72  10 103  8 1.4 3.7
Feces DON 54  10 63  5 85  9 3.4 11.2
D3G 52  10 62  14 95  12 2.6 8.7
DOM-1 59  9 59  4 89  6 3.2 10.8
a Apparent recovery.
b Signal suppression/enhancement.
c Extraction recovery.
d Limits of detection and quantiﬁcation in spiked measurement solutions.
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in urine was validated in a working range of 3–100 ng/mL in the
measurement solution. For feces, method performance character-
istics were determined for DON, DOM-1 and D3G in a working
range between 30 and 300 ng/mL. Data evaluation was performed
as stated in Nagl et al. (2012). Since oral DON and D3G
administrations were incomplete in one of the piglets, data from
the respective animal were not included in the calculations.
3. Results and discussion
3.1. Sample preparation and method performance
Interfering matrix components can represent a major challenge
in analysis of DON and its metabolites in biological samples,
especially in urine (Gambacorta et al., 2013; Warth et al., 2011).
During method development, different sample clean-up techni-
ques, including solid phase extraction, salting-out assisted liquid–
liquid extraction and dilute-and-shoot (DAS), were tested. Since
DAS comprised satisfactory apparent recoveries of analytesFig. 2. SRM chromatogram (— m/z 471 !113, - - - m/z 471 ! 265) of DON-3-GlcA and DO
ion scans (inlays, collision energy = 40 eV) the fragmentation product of m/z 471 !441 (56–114%) and simple sample preparation, this approach was
chosen for ﬁnal analysis of urine samples. Due to the dilution of
samples by a factor of 10, overall limits of detection (LODs, S/N = 3)
for DON, D3G, DON-3-GlcA and DOM-1 were 9, 13, 90 and 14 ng/
mL, respectively. Corresponding limits of quantiﬁcation
(LOQs, S/N = 10) of 80, 21, 373 and 37 ng/mL were obtained. In
standard solutions, LODs and LOQs ranged between 0.5–3.3 and
1.5–9.4 ng/mL. Detailed results of method validation are provided
in Table 1.
Besides DON-3-GlcA, a second DON-GlcA peak was detected in
contaminated urine samples (Fig. 2). Further investigations of this
peak by MS/MS experiments and enzymatic treatment according
to Warth et al. (2012) suggested the presence of DON-15-GlcA.
Most prominently, a fragment of m/z 441 (resulting from the loss of
CH2O from C15) is observed in DON-3-GlcA, but not in DON-15-
GlcA (see inlays of Fig. 2). Due to the lack of a suitable standard,
quantiﬁcation of DON-15-GlcA was performed using DON-3-GlcA
calibrants. The comparatively higher MS response of DON-15-GlcA
reported by Warth et al. (2012) was veriﬁed with our instrumental
setup and taken into consideration for all further calculations
(correction factor 1.88).
For feces, sample preparation consisted of a three step
extraction, followed by protein precipitation. Reduced apparent
recoveries (54–59%) were caused by matrix suppression rather
than by insufﬁcient extraction of analytes (Table 1). Dilutions of the
samples by a factor of 56 resulted in LODs of 188, 146, 179 ng/g for
DON, D3G and DOM-1, respectively, while corresponding LOQs of
626, 486 and 605 ng/g were determined.
To sum up, matrix interferences could be observed for both
matrices and all analytes. Although their extent was reduced to a
level acceptable for analysis of our samples, the importance of a
validation for each analyte–matrix combination was once more
highlighted.
3.2. Clinical symptoms
DON can cause severe adverse health effects in pigs, e.g.,
anorexia, emesis or weight loss (reviewed by Pestka, 2007). Due toN-15-GlcA in a urine sample of a piglet orally dosed with DON. In enhanced product
is absent in the second DON-GlcA-isomer, suggesting the presence of DON-15-GlcA.
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toxins’ oral bioavailability (in case of emesis), amounts of
administered toxins were chosen on the basis of no observed
adverse effect levels for oral (Forsyth et al., 1977), and intravenous
DON application (Prelusky, 1993; Prelusky and Trenholm, 1993) in
pigs, respectively. Independent of the treatment, neither retching
nor emesis was observed in any of the animals. Feed intake was
noticed for all piglets within 30 min after toxin administrations.
3.3. Detected amounts of excreted toxins in urine and feces
In the individual sampling periods, volumes of collected urine
ranged between 22 and 838 mL per piglet, while amounts of
freeze-dried feces varied between 2 and 22 g. In urine, concen-
trations of DON, D3G, DON-3-GlcA, DON-15-GlcA and DOM-1 were
between 105 and 1420 ng/mL, 50.6 and 1100 ng/mL, 542 and
1030 ng/mL, 198 and 705 ng/mL and 84.8 and 501 ng/mL,
respectively. Of all the analytes tested only DOM-1 was found in
feces, with concentrations ranging between 914 and 1220 ng/g. To
facilitate comparability between the excreted amounts of different
toxins, results are expressed as molar amounts henceforth.
3.3.1. Negative control (water administration)
After oral application of water, traces of DON could be
determined in urine samples of the ﬁrst sampling period (Table 2).
The provided feed was analyzed for DON, D3G, 3-ADON and 15-
ADON before the start of the experiment and additional feed
samples were taken on each of the treatment days. LC–MS/MS
measurements revealed low concentrations of DON (67  28 mg/
kg) in the diet, whereas none of the other analytes could be
quantiﬁed (LOQs 20 mg/kg). Thus, the minimal DON contamination
of the diet already led to detectable DON concentrations in urine.
However, the daily amount of DON ingested via feed reﬂected only
2% of the toxin doses administered in the following treatments
and was therefore not considered in further calculations.
3.3.2. Oral DON administration
Following oral administration of DON, we found DON, DON-3-
GlcA and DON-15-GlcA in urine of piglets. The majority of
analytes was excreted in the ﬁrst sampling period (Table 2), thus
conﬁrming a fast elimination of the mycotoxin (Pestka, 2007).
DON was the major urinary metabolite, representing 62.1 6.2%
of the total analytes excreted in urine. The percentage ofTable 2
Total amounts of recovered DON, D3G, DON-3-GlcA, DON-15-GlcA and DOM-1 in urine 
listed for the indicated time periods after oral administration of water, DON (0.25 mmol
(0.03 mmol/kg b.w.). Since oral toxin administrations were incomplete in one of the an
Treatment Matrix Time period (h) DON  SD (nmol) D3G  SD (nmol) 
Water oral
(n = 4)
Urine 0–8 1.9  3.9 n.d. 
8–24 n.d. n.d. 
Feces 0–8 n.d. n.d. 
8–24 n.d. n.d. 
DON oral
(n = 3)
Urine 0–8 880  220 n.d. 
8–24 310  91 n.d. 
Feces 0–8 n.d. n.d. 
8–24 n.d. n.d. 
D3G oral
(n = 3)
Urine 0–8 140  150 44  33 
8–24 330  130 15  4 
Feces 0–8 n.d. n.d. 
8–24 n.d. n.d. 
D3G i.v.
(n = 4)
Urine 0–8 12  24 410  27 
8–24 n.d. 16  11 
Feces 0–8 n.d. n.d. 
8–24 n.d. n.d. 
n.d.: not detected (analyte concentration in all samples <LOD).glucuronidated DON in pig urine (37.9  6.2%) corresponds to
values obtained in previous studies (Dänicke et al., 2005;
Sundstøl Eriksen et al., 2003), in which DON-GlcA was deter-
mined via indirect methods (enzymatic hydrolysis). Yet higher
glucuronidation rates were observed in other species (Meky et al.,
2003; Warth et al., 2012). A comparably low activity of porcine
UDP-glucuronosyltransferases, as shown by Maul et al. (2012),
may account for this phenomenon.
Inrecentyears, special focushas beenputnotonlyon the extentof
glucuronidation, but also on species-dependent variations regarding
the formation of different DON-GlcA isomers. Lattanzio et al. (2011)
were the ﬁrst to postulate the presence of two DON-GlcA conjugates
in rat urine, while Warth et al. (2012) successfully identiﬁed DON-3-
GlcA and DON-15-GlcA in urine of humans. In addition, evidence for
the formationof furtherDON-GlcAshasbeen given(Mauletal., 2012;
Nagl et al., 2012; Uhlig et al., 2013; Warth et al., 2013). To the best of
our knowledge, the present study provides ﬁrst in vivo data on the
occurrence of different DON-GlcA isomers in pigs. Besides DON-3-
GlcA, a second conjugate was detected in the urine of DON exposed
piglets and was tentatively identiﬁed as DON-15-GlcA. While the
latter was found tobe the predominantconjugate in humans (Warth
et al., 2012, 2013), ratios of DON-15-GlcA to DON-3-GlcA varied
between individual piglets (0.5–2.2). Further studies are needed to
investigate this aspect in more detail.
The high susceptibility of pigs to DON is often related to the
species’ poor ability to degrade DON to DOM-1 (Pestka 2007). In
our experiment, DOM-1 could not be detected in urine or feces
samples following DON indigestion. Moreover, none of the
analytes included in our LC–MS/MS method seemed to be present
in feces of piglets dosed with DON. While a complete lack of DOM-
1 formation in swine is reported in literature (Sundstøl Eriksen
et al., 2002), the absence of any toxins in feces may be due to
several reasons. First, dilution of feces samples resulted in higher
LODs and LOQs than in urine, thus raising the possibility that
minimal toxin amounts were not detectable. More importantly,
DON is primarily eliminated via urine in pigs. Since excreted toxin
amounts in feces were reported to account for only 0.1–3% of the
administered dose (Goyarts and Dänicke, 2006; Dänicke and
Brezina, 2013), our results are not in conﬂict with previous studies.
3.3.3. Oral D3G administration
In urine of piglets orally dosed with D3G, the masked mycotoxin
itself, as well as DON, DON-3-GlcA, DON-15-GlcA and DOM-1 couldand feces of dosed piglets, respectively. Mean values  standard deviations (SD) are
/kg b.w.) and D3G (0.25 mmol/kg b.w.) as well as after intravenous D3G application
imals, data from the respective piglet were excluded.
DON-3-GlcA  SD (nmol) DON-15-GlcA  SD (nmol) DOM-1  SD (nmol)
n.d. n.d. n.d.
n.d. n.d. n.d.
n.d. n.d. n.d.
n.d. n.d. n.d.
280  240 280  50 n.d.
170  65 62  40 n.d.
n.d. n.d. n.d.
n.d. n.d. n.d.
27  35 44  70 125  52
45  11 100  34 n.d.
n.d. n.d. 44  41
n.d. n.d. n.d.
n.d. n.d. n.d.
n.d. n.d. n.d.
n.d. n.d. n.d.
n.d. n.d. n.d.
V. Nagl et al. / Toxicology Letters 229 (2014) 190–197 195be found. Amounts of urinary excreted D3G were low, especially in
the second time period (15  4 nmol). A limited bioavailability of
D3G has already been shown for rats (Nagl et al., 2012). In a human
volunteer consuming a diet naturally contaminated with D3G
(7 mg D3G/day), the masked mycotoxin could not be detected in
urine at all (Warth et al., 2013). A likely explanation for these
ﬁndings is provided by De Nijs et al. (2012) who showed that D3G is
far less absorbed by human intestinal Caco-2 cells compared to
DON. Taking into consideration both the limited bioavailability of
D3G and its lower biological activity on the ribosomal level
(Poppenberger et al., 2003) data indicate so far that D3G is less
toxic than its parent toxin in mammals.
Yet major concerns have been raised regarding a possible
hydrolysis of D3G with subsequent release of its aglycon in the
digestive system. Results of several in vitro studies have supported
these suggestions (Berthiller et al., 2011; Dall´ Erta et al., 2013; Gratz
et al., 2013), while in vivo reports on the issue are rare and only
available for rats (Nagl et al., 2012; Veršilovskis et al., 2012). In the
present experiment, DON as well as DON-15-GlcA and DON-3-GlcA
were found in urine of piglets after oral D3G administration,
conﬁrming that D3G is cleaved to DON, absorbed and metabolized
to DON-GlcA in pigs. Since these ﬁndings correlate well with those
observed in rats (Nagl et al., 2012), hydrolysis of ingested D3G
seems not to be species-dependent, but potentially a common
feature of mammals in general. Notably, urinary excreted amounts
of DON and DON-GlcA increased in samples of the second sampling
period, with DOM-1 solely being detectable 8–24 h after dosing
(Table 1). Consistently, DOM-1 was also found in feces samples of
this time period. In pigs, this metabolite is known to be mainly
formed in the hindgut (Dänicke et al., 2004a). With respect to the
seemingly low absorption of D3G in the small intestine (De Nijs
et al., 2012), it is likely that relevant amounts of the masked
mycotoxin reach distal parts of the gut, where they are hydrolyzed
to DON, further metabolized to DOM-1 and absorbed. This scenario
would explain the differences between the oral DON and D3G
treatments regarding both the presence of DOM-1 in investigated
matrices as well as the delayed urinary excretion of D3G
metabolites. However, further speciﬁc study designs are necessary
to verify this hypothesis.
3.3.4. Intravenous D3G administration
The vast majority of intravenously administered D3G was
excreted in unmetabolized form via urine in the ﬁrst sampling
period (Table 2). In contrast, only traces of urinary DON could be
detected, whereas none of the other analytes was found.
Berthiller et al. (2011) have shown that human cytosolicFig. 3. Excretion of DON, D3G and their metabolites in urine and feces of toxin exposed pib-glucosidase, an enzyme expressed in liver, kidney, spleen
and gut (Berrin et al., 2002), had no activity with D3G. In
agreement, our data strongly indicate that hydrolysis of D3G is
marginal after systemic absorption (or even not occurring at all
if taking into account that low levels of urinary DON were also
detected after water administration). As a consequence, we
suppose that in vivo cleavage of D3G predominantly occurs in
the digestive tract.
3.4. Total recoveries
The quantitative urinary recovery of DON allows an appropriate
estimation of the toxin’s bioavailability in pigs (Goyarts and
Dänicke, 2006). After oral administration of DON, 84.8  9.7% of the
administered dose were detected in urine within 24 h in total
(Fig. 3). Unmetabolized DON accounted for 51.4  6.3%, while DON-
3-GlcA and DON-15-GlcA reﬂected 19.0  6.8% and 14.5 1.8% of
the applied toxin dose, respectively. The high oral bioavailability of
DON is in line with literature reports, where urinary DON
recoveries between 44 and 82% were assessed after single oral/
intragastric DON administration (Dänicke et al., 2004b; Prelusky
et al., 1988). Furthermore, urinary recoveries determined in our
study are comparable to those observed in humans (summarized
by Turner et al., 2012) underlining once more the similarities
between those species in regard to DON metabolism.
Following oral D3G application, the overall amount of
recovered analytes reﬂected 42.1 8.5% of the administered toxin
dose. Thereof, urinary excreted metabolites represented
40.3  10.0%, whereas elimination via feces accounted for only
1.8  1.6%. Although the primary excretion route of D3G seems to
differ between pigs and rats, the low oral bioavailability of the
masked mycotoxin applies for both species: urinary D3G
accounted for 2.6  1.4% in our study, while amounts of
0.3  0.1% were reported for rats (Nagl et al., 2012). DON, DON-
3-GlcA, DON-15-GlcA and DOM-1 in piglets’ urine reﬂected
21.6  3.7%, 3.4  2.0%, 6.8  4.1% and 5.9  2.9% of the adminis-
tered dose, respectively. Despite the nearly complete hydrolysis
and metabolization of D3G, the absorption of the formed
metabolites seems to be limited. In comparison to DON treatment,
the proportion of urinary excreted metabolites was reduced by a
factor of 2, approximately. DON is predominantly absorbed in
proximal parts of the small intestine in pigs (Dänicke et al., 2004a),
whereas in vitro experiments indicate that D3G is hydrolyzed
thereafter (Berthiller et al., 2011; Dall´Erta et al., 2013). Thus, the
obtained in vivo data are not entirely surprising. Still, also non-
absorbed hydrolysis products of D3G could exhibit adverse healthglets. Values are expressed as DON equivalent percentages of the administered dose.
196 V. Nagl et al. / Toxicology Letters 229 (2014) 190–197effects. For example, DON was shown to induce intestinal damage
by alteration of tight junction protein expression and decrease of
the barrier function (Pinton et al., 2009). Data dealing with
possible effects of D3G and its degradation products on the gut
health are lacking so far.
Yet another question of interest is the discrepancy in the overall
recovered toxin amounts between oral DON and D3G treatment.
One explanation might be an incomplete elimination of D3G by
24 h, as indicated by the considerable amounts of urinary excreted
analytes 8–24 h after dosing. Thus, the short sampling period
represents a limitation of our study. Moreover, we cannot ensure
that the employed biomarker method includes all metabolites and
degradation products which are actually formed of D3G in vivo. For
example, novel sulfated DON metabolites have been identiﬁed in
rats and chicken just recently (Wan et al., 2014). Furthermore,
some intestinal bacteria may be able to use the phosphorelay
uptake system and convert D3G into DON-3-phosphoglucoside,
but are inefﬁcient to cleave this metabolite into DON and glucose-
phosphate. Currently, no standard is available for DON-3-
phosphoglucoside. Also the formation of other (fecal) metabolites
cannot be excluded. However, to encounter this problem to some
extent, we investigated the presence of DOM-1-glucuronide
(DOM-1-GlcA) in urine samples. Enzymatic treatment resulted
in an increase of DOM-1 concentrations in urine of piglets orally
dosed with D3G by a factor of 3.5 on average, thus indicating the
presence of DOM-1-glucuronide. Due to a lack of a suitable
standard, this metabolite was not quantiﬁed in our study. In
comparison, an extensive metabolization of the masked mycotoxin
after its systemic absorption seems rather unlikely, since almost
the complete amount of intravenously administered D3G was
recovered in unmetabolized form in urine (99.9  8.9% out of
102.4  5.4% total recovery). In the future, the investigation and
identiﬁcation of unaccounted D3G metabolites, especially of those
formed by gut microbiota, using high resolution mass spectrom-
eters will be a major task.
In conclusion, we demonstrated that ingested D3G is nearly
completely hydrolyzed in pigs, but only partially absorbed. Results
indicate that the cleavage predominantly occurs in the digestive
tract, while the toxin seems to be rather stable after systemic
absorption. Compared to DON, the proportion of urinary excreted
metabolites after oral D3G administration was reduced by a factor
of 2, approximately. Based on these data we presume that D3G is
less bioavailable than its parent toxin in pigs and therefore of lower
toxicological relevance. However, the bioavailability of D3G in pigs
may increase after chronic exposure via feed, as it has already been
shown for DON (Goyarts and Dänicke, 2006). Clariﬁcation of this
aspect will be also important regarding the risk assessment of D3G
and its potential implementation in regulatory limits. Further-
more, it should be emphasized that D3G may exhibit biological
activity on its own. Therefore, future studies should for instance
address possible emetic effects of the masked mycotoxin or its
inﬂuence on intestinal gut health.
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